论文部分内容阅读
目的研究胰腺癌化疗后应用树突状细胞-细胞因子诱导的杀伤(dendritic cells-cytokine induced killer,DCCIK)细胞对患者免疫功能的影响和疗效。方法回顾性分析从2011年3月—2013年2月于本院进行治疗的100例胰腺癌患者的临床资料。根据治疗方法的不同分为观察组(50例)、对照组(50例)。所有患者均进行化疗治疗,而观察组在此基础上联合自身DC-CIK细胞进行治疗,对比两组患者免疫功能以及临床疗效。计量资料采用t检验,计数资料采用χ~2检验,P<0.05为差异有统计学意义。结果治疗前两组患者免疫指标对比差异无统计学意义(P>0.05),分别治疗后观察组患者CD_3~+、CD_4~+、CD_3~+CD_(56)~+水平均显著高于对照组[(67.9±3.1)%、(59.7±5.4)%、(35.2±5.9)%、(27.8±4.7)%、(13.8±2.6)%、(7.3±1.9)%],对比差异均有统计学意义(均P<0.05),而CD8~+水平明显低于对照组[(29.7±3.5)%、(39.6±5.9)%],对比差异有统计学意义(P<0.05)。观察组患者1年、3年存活率分别为88.00%、54.00%,均显著高于对照组的62.00%、32.00%,对比差异均有统计学意义(均P<0.05)。结论胰腺癌化疗后应用DC-CIK细胞治疗临床疗效显著,能有效改善患者免疫功能,提高患者存活率,安全性好,值得临床推广应用。
Objective To study the effect of dendritic cells-cytokine induced killer (DCCIK) cells on the immune function of patients after pancreatic cancer chemotherapy. Methods The clinical data of 100 patients with pancreatic cancer treated in our hospital from March 2011 to February 2013 were retrospectively analyzed. According to the different treatment methods were divided into observation group (50 cases) and control group (50 cases). All patients were treated with chemotherapy, and the observation group was combined with its own DC-CIK cells on the basis of this treatment, the immune function and clinical efficacy of the two groups were compared. Measurement data using t test, count data using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results There was no significant difference in immune indexes between the two groups before treatment (P> 0.05). After treatment, the levels of CD_3 ~ +, CD_4 ~ + and CD_3 ~ + CD_ (56) ~ + in the observation group were significantly higher than those in the control group (67.9 ± 3.1)%, (59.7 ± 5.4)%, (35.2 ± 5.9)%, (27.8 ± 4.7)%, (13.8 ± 2.6)%, (7.3 ± 1.9)%, respectively (P <0.05), while the level of CD8 ~ + was significantly lower than that of the control group [(29.7 ± 3.5)% vs (39.6 ± 5.9)%], the difference was statistically significant (P <0.05). The 1-year and 3-year survival rates in the observation group were 88.00% and 54.00%, respectively, which were significantly higher than those in the control group (62.00% and 32.00%, respectively) (all P <0.05). Conclusions The clinical efficacy of DC-CIK cells after chemotherapy for pancreatic cancer is significant, which can effectively improve the immune function and improve the survival rate of patients with good safety. It is worthy of clinical application.